We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Fecal Immunochemical Test Effective for Annual Colon Cancer Screening

By LabMedica International staff writers
Posted on 10 Feb 2016
The fecal immunochemical test (FIT) is highly sensitive for detecting colorectal cancer, and adherence to annual follow-up screening among initial participants is high, making the noninvasive test feasible and effective for annual colorectal cancer screening programs. More...


Colorectal cancer (CRC) is the second leading cause of cancer death in the USA. Evidence shows that highly sensitive guaiac-based fecal occult blood tests (FOBT), which are recommended for annual screening of average risk patients between the ages of 50 and 75, can reduce morbidity and mortality from colorectal cancer. FIT has higher detection rates for CRC and advanced adenomas than FOBT, but little is known about how well FIT works over several rounds of annual screening.

Scientists working for Kaiser Permanente (Oakland, CA, USA) and their colleagues carried out a retrospective cohort study and collected data on 323,349 health plan members aged 50 to 70 years. The members were on their FIT mailing date in 2007 or 2008 and had completed the first round of FIT and were followed for up to four screening rounds. Screening participation included an FIT positivity, equal to or greater than 20 µg of hemoglobin/g, which has positive predictive values for adenoma and CRC, and FIT sensitivity for detecting CRC obtained from Kaiser Permanente electronic databases and cancer registries.

Of the patients invited for screening, 48.2% participated in round one. Of those who remained eligible, 75.3% to 86.1% participated in subsequent rounds. Median follow-up was 4.0 years, and 32% of first round participants crossed over to endoscopy over four screening rounds and 7.0% were due to a positive FIT result. The FIT positivity rate of 5.0% and positive predictive values (adenoma, 51.5%; CRC, 3.4%) were highest in the first round.

Overall, programmatic FIT screening detected 80.4% of patients with CRC diagnosed within one year of testing, including 84.5% in round one and 73.4% to 78.0% in subsequent rounds. The authors concluded that annual FIT screening was associated with high sensitivity for CRC, with high adherence to annual follow-up screening among initial participants. The findings indicate that annual programmatic FIT screening is feasible and effective for population-level CRC screening. The study was published on January 26, 2016, in the journal Annals of Internal Medicine.

Related Links:

Kaiser Permanente



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Hematology Consumables
Bioblood Devices
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
An overview of the study and findings: A) Several brain-derived EVPs cross the blood brain barrier and reach circulation. B) Different EVPs enrich different RNA cargo B) The EVP-RNA is impacted, upregulated (green) or downregulated (red) in AD (Gonzalez-Kozlova, E., et al., Nature Communications (2026). doi.org/10.1038/s41467-026-74541-8)

RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis

Alzheimer’s disease affects an estimated 55 million people worldwide and remains difficult to diagnose at an early stage. Diagnostic workups can be complicated by symptom overlap with other conditions,... Read more

Microbiology

view channel
Image: Multidrug-resistant Klebsiella pneumoniae is a growing community health concern, causing recurrent UTIs in older adults and complicating first-line antibiotic treatment (Image Credit: Adobe Stock)

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.